Výsledky vyhledávání - "Khadeja A. Moses"

Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas

Autor: Arielle Elkrief, Alex Makhnin, Khadeja A. Moses, Linda S. Ahn, Isabel R. Preeshagul, Afsheen N. Iqbal, Sara A. Hayes, Andrew J. Plodkowski, Paul K. Paik, Marc Ladanyi, Mark G. Kris, Gregory J. Riely, Franziska Michor, Helena A. Yu

Publikováno v: Clinical Cancer Research. 29:1423-1428

Purpose: Primary and acquired resistance to osimertinib remain significant challenges for patients with EGFR-mutant lung cancers. Acquired EGFR alterations such as EGFR T790M or C797S mediate resistance to EGFR tyrosine kinase inhibitors (TKI) and co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::54f4f625ed5f97d1b7e414751e5f95a4
https://doi.org/10.1158/1078-0432.ccr-22-3484

Zobrazit plný text záznamu

Supplemental Figure 1 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas

Autor: Helena A. Yu, Franziska Michor, Gregory J. Riely, Mark G. Kris, Marc Ladanyi, Paul K. Paik, Andrew J. Plodkowski, Sara A. Hayes, Afsheen N. Iqbal, Isabel R. Preeshagul, Linda S. Ahn, Khadeja A. Moses, Alex Makhnin, Arielle Elkrief

Supplemental Figure 1. Dose modifications of Combination Osimertinib and Dacomitinib (initial therapy study).

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80c64047c576307a4e9d5e188c4c469b
https://doi.org/10.1158/1078-0432.22632971.v1

Zobrazit plný text záznamu

Supplemental Figure 4 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas

Supplemental Figure 4. A. Median progression-free survival and B. Overall survival for patients enrolled in the acquired resistance study

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10d58e9d9523326d1f9db1fbe06b7815
https://doi.org/10.1158/1078-0432.22632962.v1

Zobrazit plný text záznamu

Supplemental Figure 3 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas

Supplemental Figure 3. A. Median progression-free survival and B. Overall survival for patients enrolled in the initial therapy study

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1787c7367d2892ace2a1d49ed62c869c
https://doi.org/10.1158/1078-0432.22490464

Zobrazit plný text záznamu

Supplemental Figure 2 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas

Supplemental Figure 2. Dose modifications of Dacomitinib +/- Osimertinib (acquired resistance study).

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22e1611fe736d1bb322b395996ea6b5f
https://doi.org/10.1158/1078-0432.22490467

Zobrazit plný text záznamu

Supplementary Table 1 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas

Supplemental Table 1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc9da03b1490517c4381387ca858292b
https://doi.org/10.1158/1078-0432.22490458

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání